Selective resistance profiles emerging in patient-derived clinical isolates with cabotegravir, bictegravir, dolutegravir, and elvitegravir.
Maureen OliveiraRuxandra-Ilinca IbanescuKaitlin AnstettThibault MésplèdeJean-Pierre RoutyMarjorie A RobbinsBluma G Brennernull nullPublished in: Retrovirology (2018)
Second generation INSTIs show a higher genetic barrier to resistance than EVG and RAL. The potency of CAB was lower than BIC and DTG. The development of Q148R/K with CAB can result in high-level cross-resistance to all INSTIs.
Keyphrases